Siga Technologies INC: insider trades · United States · SEC (Form 4)

About Siga Technologies INC

SIGA Technologies, Inc. is a United States biopharmaceutical company listed on the Nasdaq Global Market, with headquarters in New York. Founded in the 1990s, SIGA has evolved into a highly focused medical-countermeasures and biodefense specialist. Unlike diversified pharmaceutical groups, the company is centered on a narrow portfolio built around its lead asset, TPOXX® (tecovirimat), an antiviral designed for the treatment of human smallpox and, in certain jurisdictions, other orthopoxvirus-related conditions. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001010086/000143774925007056/siga20241231_10k.htm?utm_source=openai)) SIGA’s business model is primarily anchored in government procurement and public-health preparedness. The company sells TPOXX largely to the U.S. government and to international government customers or government-affiliated entities. That makes SIGA a niche supplier at the intersection of healthcare, national security, and biodefense readiness. The upside of this model is that it offers a strategic position in a highly specialized category with long-duration institutional relationships; the trade-off is a high degree of concentration around a single commercial platform and a limited number of customers and contract channels. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1010086/000143774926007557/siga20251231_10k.htm?utm_source=openai)) From a competitive standpoint, SIGA is not trying to compete head-on with broad-based pharmaceutical companies. Its market position is more akin to a strategic biodefense provider with expertise in antiviral countermeasures. Management describes its growth strategy around four priorities: sustaining its partnership with the U.S. Government, advancing regulatory approvals for TPOXX in new indications and formulations, expanding global access through strategic partnerships, and leveraging its capabilities into adjacent therapeutic areas. ([investor.siga.com](https://investor.siga.com/?utm_source=openai)) TPOXX is SIGA’s flagship product and the core of the company’s commercial identity. Recent company disclosures indicate that oral TPOXX is approved in the U.S. and Canada for smallpox, and authorized in Europe, the UK, and Japan for smallpox, mpox (monkeypox), cowpox, and complications following smallpox vaccination. SIGA also continues to work on additional formulations and regulatory pathways, including pediatric development work and potential U.S. label expansion efforts. ([investor.siga.com](https://investor.siga.com/investors/news/news-details/2025/SIGA-Reports-Financial-Results-for-Three-and-Nine-Months-Ended-September-30-2025/default.aspx?utm_source=openai)) Recent milestones reinforce the company’s specialized profile. In May 2026, SIGA reported first-quarter 2026 results and said it remained on track to deliver approximately $13 million of oral TPOXX to an international customer in the second quarter of 2026. The company has also indicated a potential 2026 supplemental NDA submission in the U.S. for a smallpox post-exposure prophylaxis indication, subject to ongoing analysis. For investors, SIGA remains a high-conviction specialty healthcare name whose performance is closely tied to government demand, regulatory developments, and biodefense procurement cycles. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1010086/000114036126019538/ef20072552_ex99-1.htm?utm_source=openai))